This invention relates to a deproteinized calf blood preparation for use in the prophylaxis or treatment of diabetic peripheral polyneuropathy, where the deproteinized calf blood preparation is administered parenterally at least once and where the parenteral administration is followed by an enteral administration period. Preferably, 20 doses of a deproteinized calf blood preparation are administered intravenously once a day for a period of 20-36 days, followed by oral administration of a deproteinized calf blood preparation for 140 days. In a preferred embodiment of the present invention, the deproteinized calf blood preparation is the drug Actovegin®.
展开▼
